Clinical Evidence Human Trials: A randomized, placebo-controlled study in obese adults demonstrated that AOD-9604 significantly reduced abdominal and total body fat over several weeks of treatment, without serious side effects Animal Studies: Preclinical studies in mice and rats showed that AOD-9604: Stimulated lipolysis Inhibited lipogenesis (formation of new fat) Prevented weight gain despite high-fat diets This dual actionenhancing fat breakdown and inhibiting fat formationpositions AOD-9604 as a potent tool for combating obesity
Dual asparaginedepriving nanoparticles against solid tumors
The following antibodies were used for immunofluorescence: anti-4HNE (1:200, Abcam, ab46545), anti-GPX4 (1:400, Abcam, ab125066) and anti-GR-1 (1:100, BioLegend, 108413) as primary antibodies and anti-rabbit IgG Alexa Fluor 488 (1:1000, Invitrogen, A-11034) and anti-rat IgG Alexa Fluor 594 (1:1000, Invitrogen, A-11007) as secondary antibody
D'Angelo and Selhub, 1997)